Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: May 2012

12 05, 2012

More about Revlimid and secondary cancer risk

Tags: , , , , , , , |20 Comments

Concerned about FDA secondary cancer warnings when using Revlimid? Dr. James Berenson helps patients understand a new FDA investigation regarding the use of lenalidomide (Revlimid) and thalidomide in a timely interview by Patient Power founder and host, Andrew Schorr. Dr. Berenson also comments on a new study from Sweden regarding increased risk of blood clots

7 05, 2012

BREAKING NEWS: Perifosine Stage 3 trial will proceed!

Tags: , |2 Comments

When perifosine failed to extend overall survival (OS) in patients with metastasized colorectal cancer recently in a Stage 3 trial, company officials and financial analysts speculated that plans to start a stage 3 multiple myeloma theory might be scrapped: Ouch!  Will financial difficulties stop promising anti-myeloma therapy? More about perifosine's uncertain future I'm pleased to

6 05, 2012

Helpful information from our readers

Tags: , |12 Comments

I have already heard from several fellow myeloma patients that are willing to share their stories after reading Friday's post: WE WANT TO READ ABOUT YOU!  In the meantime, I have a number of other interesting reader contributions that I would like to share with you. The first is from a regular reader who recently

5 05, 2012

Skeletal surveys aren’t acurate enough


Normally I would relegate information like this to my site.  But this is important--really important. For me, skeletal surveys--sometimes referred to as bone mapping or bone surveys--are practically a waste of time.  When I was originally diagnosed, X rays showed almost nothing--no bone damage.  There was a possible fracture at my T-12 vertebra,  But

3 05, 2012

French researchers identify why some myeloma patients live longer

Tags: , , |2 Comments

Multiple myeloma researchers have spent the last decade trying to determine which patients are high risk and less likely to respond favorably to treatment. This report is encouraging.  It focuses on ways to identify patients who are likely to live LONGER than median life expectancy numbers would indicate. Mary Ann Moon does a good job